Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patien...
Հիմնական հեղինակներ: | Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2011
|
Նմանատիպ նյութեր
-
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
: Pichavant, C, և այլն
Հրապարակվել է: (2011) -
Utrophin upregulation in DMD therapy: current status and new tools for the future
: Fairclough, R, և այլն
Հրապարակվել է: (2011) -
DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
: Remko Goossens, և այլն
Հրապարակվել է: (2023-12-01) -
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model
: SongTing Shi, և այլն
Հրապարակվել է: (2011-02-01) -
DMD and West syndrome
: Cardas, R, և այլն
Հրապարակվել է: (2017)